Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.81 | N/A | +13.43% |
management commentary, guidance changes, and full analysis available with Pro.
| +13.43% |
Tone: Cautiously Optimistic
Management highlighted the positive EPS surprise as a sign of resilience. They emphasized their commitment to innovation and future growth.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
The company remains focused on its long-term growth strategy.
Amgen's earnings report showed a strong EPS performance, exceeding expectations, which led to a slight increase in the stock price. However, the lack of revenue figures and guidance may leave investors cautious. The minimal stock reaction suggests that the market was already anticipating a solid EPS result.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ON SEMICONDUCTOR COR
Feb 1, 2021